Delivery time2024-10-20 07:00
Peptron and Inventage Lab join forces with global pharmaceutical companies… Also applied to schizophrenia and hair loss treatment
injection
[게티이미지뱅크 제공]
(Seoul = Yonhap News) Reporter Kim Hyun-soo = Technology that releases drugs slowly and literally allows ‘one injection that would otherwise be administered multiple times’ is attracting attention from the domestic and foreign pharmaceutical industry.
According to the pharmaceutical and bio industry on the 20th, domestic bio company Peptron[087010]signed a joint research agreement with Eli Lilly, a major U.S. pharmaceutical company, to evaluate the technology of a long-acting injectable drug platform.
Eli Lilly, the developer of the obesity treatment drug ‘Maunjaro’ (ingredient name: Tirzepatide, US name: Zebbound), is a so-called ‘Big Pharma’ (large global pharmaceutical company) that ranked first in market capitalization among global pharmaceutical companies last year.
According to the contract, the two companies plan to conduct joint research to apply Peptron’s ‘SmartDepot’ technology to many of Lilly’s peptide drugs.
‘Depot’, which means warehouse or storage, is used in pharmaceutical terms to mean ‘drug storage’ that is slowly released into the tissue. It is also a type of ‘sustained-release’ technology that controls drug release.
According to Peptron, ‘Smart Depot’ is a microsphere formulation manufacturing technology with long-lasting drug efficacy, and is characterized by controlling the drug release rate using biodegradable polymers.
Inventage Lab, a drug delivery system platform company[389470]The company announced last month that it had signed a joint development agreement with German global pharmaceutical company Boehringer Ingelheim to develop a long-acting injectable drug.
Inventage Lab plans to use the ‘IVL-DrugFluidic’ platform to develop a long-acting injectable candidate formulation based on Boehringer Ingelheim’s new drug candidate.
Such long-lasting technology is attracting particular attention in the field of obesity treatment development.
Considering that the obesity treatments developed so far have to be administered once a week, simply increasing the dosing cycle can make the product more competitive.
As the expiration of patents for obesity treatment approaches, generic drugs with similar formulations may appear one after another, which is why pharmaceutical companies are working hard to develop products that are differentiated from existing formulations.
The patent for liraglutide, the main ingredient in Danish pharmaceutical company Novo Nordisk’s obesity treatment ‘Saxenda’, expires next month, and competition to develop biosimilars (biopharmaceutical generic drugs) is intensifying. ‘Semaglutide’, the main ingredient in this company’s other obesity treatment drug ‘Wegobee’, also has its national patent expiration from 2026.
Yuhan Corporation and Inventage Lab “Jointly develop long-acting injectable drug for obesity treatment”
(Seoul = Yonhap News) Inventage Lab, a long-acting injectable drug development company, is affiliated with Yuhan Corporation.[000100]announced on the 5th that it had signed an agreement to jointly develop a long-acting injectable drug for the treatment of obesity and diabetes. The photo shows Inventage Lab CEO Kim Joo-hee (left) and Yuhan Corporation President Kim Yeol-hong taking a commemorative photo after signing the agreement. 2024.1.5 [인벤티지랩 제공. 재판매 및 DB 금지] photo@yna.co.kr
One of the motivations for development is that long-acting injectables are relatively difficult to develop compared to existing treatments such as oral medications, which can delay the emergence of generic drugs.
Long-acting injectable drugs are considered an effective formulation for improving drug compliance in patients with schizophrenia, whose risk of relapse increases when they stop taking the drug.
Janssen Korea’s ‘Invega Hapiera’, which has efficacy lasting up to 6 months with a single injection, is a representative treatment for schizophrenia that has been covered by domestic insurance.
In the field of hair loss treatment, Chong Kun Dang and Daewoong Pharmaceutical are developing long-term treatments.
However, long-acting injections can also cause pain and hypersensitivity at the injection site, and the problem of ‘initial excessive release’, in which too much drug is released immediately after administration, is considered a problem that needs to be solved.
An official from the pharmaceutical and bio industry said, “All drugs always have side effects,” and “even long-acting injectable drugs must prove their effectiveness through clinical trials.”
hyunsu@yna.co.kr
Report via KakaoTalk okjebo
Unauthorized reproduction/redistribution, AI learning and use prohibited>
2024/10/20 07:00 Sent
